Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis
NCT ID: NCT06833749
Last Updated: 2025-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
600 participants
INTERVENTIONAL
2025-01-28
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Does KBP-336 lower knee pain from osteoarthritis in individuals with obesity
* Does KBP-336 lower bodyweight in the same population. Researchers will compare KBP-336 to a placebo (a look-alike substance that contains no drug) to see if KBP-336 works to pain and obesity
Participants will:
* Take KBP-336 or a placebo every week for 6 months
* Visit the clinic once every 2 weeks for checkups and tests
* Keep a diary of their symptoms and the amount of medication they use in addition to KBP-336
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of ATB-346 Versus Placebo in Osteoarthritis Patients
NCT03978208
A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA
NCT05462990
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee
NCT02126826
IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA
NCT00316784
Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee
NCT05008835
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Placebo to match KBP-336
KBP-336 Dose 1
KBP-336
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
KBP-336 Dose 2
KBP-336
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
KBP-336 Dose 3
KBP-336
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KBP-336
KBP-336 is a long acting Dual Amylin and Calcitonin Receptor agonist designed for weekly administration through subcutaneous injection.
Placebo
Placebo to match KBP-336
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willing and able to comply with study requirements and instructions
3. A diagnosis of OA of the target knee based on American College of Rheumatology (ACR) clinical and radiographic criteria(31), with OA symptoms (as reported by the participant) that have been present for at least 3 months prior to screening
4. Radiological OA grade 2 or 3 of the target knee, using the Kellgren-Lawrence method as graded by a central reader on a Fixed-Flexion X-ray obtained during screening, or on a recent (within 6 months) X-ray which fulfills the protocol specifications for reading
5. Age ≥ 45 years of either sex
6. Body Mass Index (BMI) ≥ 30 kg/m2
7. Good health, defined as no significantly relevant medical history or findings on physical examination, vital signs, ECG, and laboratory results in the opinion of the investigator.
8. Intolerance or insufficient pain relief with standard of care (e.g. physiotherapy, paracetamol, local or systemic NSAID, short term opioid use, injections of hyaluronic acid, or corticosteroids) for symptomatic OA in the index knee in the opinion of the investigator.
9. WOMAC pain subscale score in target knee at screening AND baseline ≥20 (0-50 scale)
10. Willing to withdraw from any pain medication including, but not limited to, Opioids (including semisynthetic opioids), Non-Steroidal Anti-inflammatories (NSAIDs, with the exception of low-dose aspirin for thromboprophylaxis), COX-2 inhibitors, Topical medication, and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs e.g. Duloxetine) and only use the allowed Rescue Medications from baseline to Visit 13/ET (maximum 4000 mg paracetamol per day)
Exclusion Criteria
2. Target knee surgery or arthroscopy within 1 year prior to screening
3. Diagnosis of OA resulting from trauma within the last 5 years
4. Pain of the contralateral knee exceeding that of the target knee at the baseline visit, as measured by the WOMAC pain subscale
5. Planned major surgery within the next 6 months
6. Uncontrolled thyroid disease in the opinion of the Investigator based on medical history and laboratory results collected in screening
7. Participant-reported weight loss \>5% of body weight within the last 6 months of the screening visit
8. Bariatric surgery within the last 12 months of the screening visit
9. Current comorbid condition, other than OA, affecting target knee or systemic illness known to be significantly associated with arthritis or joint pathology affecting any joint, including but not necessarily limited to endocrinopathies, inflammatory, or autoimmune disease with significant joint involvement (e.g., Rheumatoid Arthritis); Seronegative Spondyloarthropathies (e.g. Ankylosing Spondylitis, Psoriasis arthritis, Reactive arthritis)
10. Conditions significantly affecting joint and bone health, in the opinion of the Investigator should be excluded (including but not limited to atrophic or hypotrophic OA, subchondral insufficiency fracture, osteonecrosis, osteoporotic fractures, excessive malalignment of the knee or severe chondrocalcinosis)
11. Active comorbid condition other than OA (e.g radicular back pain, bursitis, tendinitis) significantly affecting target knee pain reporting in the opinion of the investigator.
12. A Patient Health Questionnaire-9 (PHQ-9) score of ≥ 15 at screening
13. History of gout, or pseudogout, with high likelihood of flare up during trial participation that would require NSAID treatment, in the opinion of the investigator
14. Hip dislocation and congenital hip dysplasia with degenerative joint disease should be excluded.
15. Participation in any previous DACRA/amylin study
16. History or presence of clinically significant neurological disease or psychiatric disorder in the opinion of the investigator
17. Intra-articular injection of corticosteroids within 3 months or hyaluronic acid within 6 months of screening in the target knee or into any other major joint within 30 days prior to screening (for extended-release corticosteroid injections: within 6 months in target knee and 3 months into any other major joint).
18. Systemic corticosteroid treatment for the treatment of musculoskeletal conditions of more than 14 days during the past 6 months prior to screening.
19. Any pharmacological or non-pharmacological treatment primarily targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study
20. Treatment with medication for obesity, including GLP-1 analogues, unless the dose of use has been stable for at least six months prior to screening
21. Vitamin D deficiency defined as blood 25-OH D3 concentration ≤25 nmol/L. Vitamin D supplementation and subsequent rescreening is allowed
22. Presence or history of clinically significant allergies, including relevant drug hypersensitivity or allergy
23. Current malignancy or treatment for malignancy within the past five years, apart from resected basal cell carcinoma, squamous skin cell carcinoma, or resected cervical atypia or carcinoma in situ, unless affecting the target knee area.
24. History of alcohol or drug abuse within 5 years prior to screening, in the opinion of the Investigator.
25. Use of an investigational drug within 90 days prior to screening
26. For women of childbearing potential:
1. Pregnancy (i.e. positive serum pregnancy test at screening) or breastfeeding
2. Failure to agree to practice a highly effective method of contraception (see Appendix 2), from enrolment up to at least 3 months after the study end
27. For sexually active men with a female partner of childbearing potential:
1. Failure to agree to ensure that their female partners use a highly effective method of contraception (see Appendix 2) from enrolment up to at least 3 months after the study end
2. Failure to agree not to donate sperm throughout the study and at least 3 months after the study end
28. Unsuitable for study participation for any reason in the opinion of the Investigator.
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KeyBioscience AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pratia Brno, s.r.o
Brno, , Czechia
L.K.N. Artrocentrum
Hlučín, , Czechia
Medical Plus, s.r.o
Hradiště, , Czechia
Pratia Pardubice a.s.
Pardubice, , Czechia
Affidea Praha s.r.o
Prague, , Czechia
Pratia Prague, s.r.o
Prague, , Czechia
Sanos Clinic Nordjylland
Gandrup, , Denmark
Sanos Clinic Herlev
Herlev, , Denmark
Sanos Clinic Syddanmark
Vejle, , Denmark
Hong Kong Center for Clinical Research
Hong Kong, , Hong Kong
IMSP Sptalul Clinic Municipal "Sfanta Treime"
Chisinau, , Moldova
PMSI Cardiology Institute/RTL SM SRL
Chisinau, , Moldova
Timofei Mosneaga Republican Clinical Hospital
Chisinau, , Moldova
NZOZ Bif-Med. s.c.
Bytom, , Poland
Medyczne Centrum Hetmańska
Poznan, , Poland
DC-MED SP z o.o.
Swidnica, , Poland
NZOZ Lecznica MAK-MED s.c.
Warsaw, , Poland
Migre Polskie Centrum Leczenia Migreny
Wroclaw, , Poland
Policlinica CCBR
Bucharest, , Romania
Quantum Medical Bucharest
Bucharest, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-517264-27-00
Identifier Type: CTIS
Identifier Source: secondary_id
KBP-336-CD-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.